Merck Net Profit Margin 2010-2022 | MRK

Current and historical net profit margin for Merck (MRK) from 2010 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue. Merck net profit margin for the three months ending December 31, 2022 was .
Merck Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2022-12-31 $59.28B $14.52B 24.49%
2022-09-30 $58.97B $15.26B 25.88%
2022-06-30 $57.17B $16.58B 29.00%
2022-03-31 $53.98B $14.18B 26.27%
2021-12-31 $48.70B $13.05B 26.79%
2021-09-30 $44.36B $7.20B 16.22%
2021-06-30 $42.14B $5.57B 13.22%
2021-03-31 $40.09B $7.03B 17.53%
2020-12-31 $41.52B $7.07B 17.02%
2020-09-30 $36.49B $11.52B 31.57%
2020-06-30 $37.96B $10.48B 27.61%
2020-03-31 $40.36B $10.15B 25.14%
2019-12-31 $39.12B $9.84B 25.16%
2019-09-30 $45.97B $9.31B 20.26%
2019-06-30 $44.37B $9.36B 21.10%
2019-03-31 $43.07B $8.40B 19.50%
2018-12-31 $42.29B $6.22B 14.71%
2018-09-30 $41.73B $3.35B 8.02%
2018-06-30 $41.26B $1.34B 3.25%
2018-03-31 $40.73B $1.58B 3.88%
2017-12-31 $40.12B $2.39B 5.97%
2017-09-30 $39.80B $2.85B 7.15%
2017-06-30 $40.02B $5.09B 12.71%
2017-03-31 $39.93B $4.35B 10.88%
2016-12-31 $39.81B $3.92B 9.85%
2016-09-30 $39.91B $5.49B 13.76%
2016-06-30 $39.44B $5.13B 13.01%
2016-03-31 $39.39B $4.61B 11.72%
2015-12-31 $39.50B $4.44B 11.25%
2015-09-30 $39.77B $10.78B 27.11%
2015-06-30 $40.25B $9.85B 24.48%
2015-03-31 $41.40B $11.17B 26.98%
2014-12-31 $42.24B $11.92B 28.22%
2014-09-30 $43.08B $5.39B 12.50%
2014-06-30 $43.55B $5.61B 12.89%
2014-03-31 $43.63B $4.52B 10.35%
2013-12-31 $44.03B $4.40B 10.00%
2013-09-30 $44.45B $4.53B 10.19%
2013-06-30 $44.91B $5.14B 11.44%
2013-03-31 $46.21B $6.02B 13.03%
2012-12-31 $47.27B $6.17B 13.04%
2012-09-30 $47.82B $6.76B 14.14%
2012-06-30 $48.36B $6.72B 13.90%
2012-03-31 $48.20B $6.95B 14.42%
2011-12-31 $48.05B $6.26B 13.02%
2011-09-30 $47.85B $4.22B 8.82%
2011-06-30 $46.95B $2.87B 6.12%
2011-03-31 $46.15B $1.60B 3.47%
2010-12-31 $45.99B $0.86B 1.87%
2010-09-30 $43.99B $7.84B 17.82%
2010-06-30 $38.91B $10.92B 28.07%
2010-03-31 $33.47B $11.73B 35.04%
2009-12-31 $27.43B $12.85B 46.86%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $263.757B $59.283B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $427.102B 16.08
Eli Lilly (LLY) United States $320.837B 42.53
Novo Nordisk (NVO) Denmark $312.448B 39.79
AbbVie (ABBV) United States $256.465B 10.63
Pfizer (PFE) United States $245.639B 6.65
Novartis AG (NVS) Switzerland $189.111B 13.99